Clinical trials: Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition frequently associated with type 2 diabetes (T2DM) and characterized by insulin resistance and hepatic fat accumulation.
- Trial name
- VA NASH (NCT01002547)
- Testing
- pioglitazone, Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Fatty Liver, Cirrhosis
Development of a Breath Test for Monitoring Patients With Liver Disease
The purpose of this study is to determine the safety and efficacy of the Oridion Breath ID machine in monitoring liver metabolic functions.
- Trial name
- NCT00244569
- Testing
- 13C-Methacetin, Breath ID Machine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Virginia Commonwealth University
NAFLD
Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis.
- Trial name
- NAFLD (NCT03587298)
- Testing
- Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
NAFLD, Liver Fibrosis
Different Doses of ZED1227 vs. Placebo in NAFLD
This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will…
- Trial name
- NormaliZED (NCT05305599)
- Testing
- ZED1227
- Where
- Germany
- Volunteers
- 186 people
- Sponsor
- Dr. Falk Pharma GmbH
Non-Alcoholic Fatty Liver Disease
Lifestyle Intervention in Fatty Liver (NAFLD)
Non-Alcoholic Fatty Liver Disease (NAFLD), including its more pathologic consequence, non-alcoholic steatohepatitis (NASH), is believed to be the most common chronic liver disease worldwide, affecting between 6 to 37% of the…
- Trial name
- FOIEGRAS (NCT03354247)
- Testing
- Lifestyle Intervention
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Bari
Non-alcoholic Steatohepatitis, Liver Diseases
Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI
This is a prospective observational study which will recruit up to 100 paediatric participants over a period of 30 months to determine whether MRI is as accurate at detecting, distinguishing, and monitoring liver disease as…
- Conditions
- Non-alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses, Autoimmune Hepatitis
- Trial name
- Kids4LIFe (NCT03198104)
- Testing
- MRI
- Where
- Poland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Perspectum
Fatty Liver
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
The purpose of this study is to assess the effect of rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH) in patients with Type 2 diabetes.
- Trial name
- NCT00577148
- Testing
- Rimonabant
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 89 people
- Sponsor
- Sanofi
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
- Trial name
- NCT06528314
- Testing
- Efruxifermin
- Where
- 345 sites in United States, Argentina and 19 more
- Volunteers
- 2,150 people
- Sponsor
- Akero Therapeutics, Inc
Non-alcoholic Fatty Liver Disease
Dietary Allowance of Methyl Donor Nutrients to Minimize Risks of Non-alcoholic Fatty Liver Progression
Investigate the methyl donors requirement of NAFLD patients to correct the malnutrition, lipid-toxicity, microbiota dysfunction, and metabolomics biomarkers.
- Trial name
- NCT05291104
- Testing
- Folic acid, choline chloride
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Fu Jen Catholic University Hospital
Non-Alcoholic Fatty Liver Disease
Pilot of Lifestyle Behavior Intervention for Non-Alcoholic Fatty Liver Disease
The purpose of this study is to pilot test a behavioral lifestyle intervention for Hispanic/Latino patients with non-alcoholic fatty liver disease (NAFLD)
- Trial name
- NCT05200585
- Testing
- Healthy Liver/Hígado Sano program, Usual standard of care
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- The University of Texas Health Science Center, Houston
Compliance Behavior
Beta Glucosylceramide for Treatment of NASH
Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.
- Trial name
- NCT02126306
- Testing
- Beta Glucosylceramide
- Volunteers
- 23 people
- Sponsor
- Hadassah Medical Organization
Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic…
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
- Trial name
- NCT05974904
- Testing
- high-sensitivity C-reactive protein to albumin ratio
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Chongqing Medical University
Rheumatoid Arthritis, Psoriasis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly…
- Conditions
- Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Diseases
- Trial name
- NCT03329885
- Testing
- BMS-986251
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Post-cholecystectomy Metabolic Changes -Hepatic Steatosis
Fatty Liver in Long Standing Cholecystectomy
This observational study aims to evaluate the association between long-term cholecystectomy and the development of metabolic dysfunction-associated fatty liver disease (MAFLD) in adult patients.
- Trial name
- MAFLD-Chole St (NCT07284004)
- Volunteers
- 100 people
- Sponsor
- Yasmeen Ahmed Farrag Ahmed
Non-alcoholic Fatty Liver Disease (NAFLD)
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
This short-term, randomized, placebo-controlled, investigator-initiated trial aims to establish metabolic improvements in NAFLD subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate…
- Trial name
- NAFLD (NCT04330326)
- Testing
- Metabolic Cofactor Supplementation, Sorbitol
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- ScandiBio Therapeutics AB
Type2 Diabetes, NAFLD
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
Non-Alcoholic Fatty Liver Disease( NAFLD) is common in patients with type 2 diabetes. Empagliflozin, an FDA-approved oral medication used to treat type 2 diabetes, has been shown to reduce production and deposition of fat in the…
- Trial name
- NCT02964715
- Testing
- Empagliflozin
- Where
- Malaysia
- Volunteers
- 25 people
- Sponsor
- University of Malaya
Liver Fat, Liver Fibrosis
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease…
- Conditions
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes
- Trial name
- Ertu-NASH (NCT05644717)
- Testing
- Ertugliflozin 5 mg, 15mg
- Where
- Pakistan
- Volunteers
- 164 people
- Sponsor
- Getz Pharma
Non-alcoholic Fatty Liver Disease (NAFLD)
Exercise Dose and Nonalcoholic Fatty Liver Disease
The purpose of this research is to provide a better understanding of how exercise (walking) affects non-alcoholic fatty liver disease (NAFLD) in overweight people.
- Trial name
- ED (NCT00771108)
- Testing
- exercise
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Insulin Resistance, Non-Alcoholic Fatty Liver Disease
The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance
The aim of this study is to investigate whether ingestion of curcumin will prevent hepatic insulin resistance (assessed by homeostatic model assessment of insulin resistance (HOMA-IR)) induced by short-term oral glucocorticoid…
- Trial name
- CURPRED (NCT04315350)
- Testing
- Curcumin Liposome, Prednisolone
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver disease, and it is increasingly diagnosed in many developed and developing countries.
- Trial name
- NCT05474560
- Testing
- Allopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.